Q3 Earnings Forecast for CORT Issued By Zacks Research

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research issued their Q3 2026 earnings per share estimates for shares of Corcept Therapeutics in a note issued to investors on Wednesday, September 16th. Zacks Research analyst Team forecasts that the biotechnology company will earn $0.65 per share for the quarter. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $2.02 per share. Zacks Research also issued estimates for Corcept Therapeutics’ FY2026 earnings at $1.39 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The business had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. During the same period in the previous year, the company posted $0.29 EPS. Corcept Therapeutics’s revenue was up 31.7% on a year-over-year basis.

A number of other equities research analysts have also weighed in on the stock. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Piper Sandler reissued an “overweight” rating and set a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Truist Financial began coverage on shares of Corcept Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price target for the company. Finally, Weiss Ratings lowered Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $138.17.

Corcept Therapeutics Stock Up 2.7%

Shares of Corcept Therapeutics stock opened at $114.86 on Friday. The firm’s 50 day moving average price is $108.19 and its 200-day moving average price is $74.96. The company has a market cap of $12.42 billion, a P/E ratio of 273.48 and a beta of 0.45. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $126.38.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total value of $6,460,963.08. Following the completion of the transaction, the insider directly owned 4,242 shares of the company’s stock, valued at $469,843.92. The trade was a 93.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kimberly Park sold 26,685 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $122.55, for a total transaction of $3,270,246.75. Following the sale, the director directly owned 30,000 shares in the company, valued at $3,676,500. This represents a 47.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 446,119 shares of company stock worth $50,644,753 over the last ninety days. Company insiders own 20.70% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Corcept Therapeutics during the 2nd quarter worth approximately $1,080,964,000. First Trust Advisors LP lifted its stake in shares of Corcept Therapeutics by 213.5% in the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after acquiring an additional 1,480,059 shares during the period. Geode Capital Management LLC increased its position in Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares during the period. Norges Bank purchased a new position in Corcept Therapeutics in the fourth quarter worth $24,213,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics in the second quarter valued at about $49,185,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks raises longer-term EPS forecasts. Zacks Research increased its estimates for Q4 2026 EPS to $0.68 from $0.62, FY2027 EPS to $2.05 from $1.91, and FY2028 EPS to $4.31 from $4.07. The firm also lifted its Q3 2027 forecast to $0.78 from $0.66, signaling improving expectations for Corcept’s earnings trajectory. Corcept Therapeutics analyst estimates
• Positive Sentiment: Commercial momentum supports the growth outlook. Korlym sales increased 6.2% in the first half of 2026, while the launch of Lifyorli could diversify revenue beyond Corcept’s established Cushing’s syndrome treatment. The company’s latest reported quarter also showed revenue growth of 31.7% year over year and EPS well above consensus estimates. Zacks report on Korlym and Lifyorli
• Neutral Sentiment: Near-term estimates are mixed. Zacks projects Q3 2026 EPS of $0.65, while its FY2026 forecast of $1.39 is below the broader consensus estimate of $2.02. This disparity may create uncertainty around the timing of earnings growth, despite more optimistic forecasts for 2027 and 2028.
• Neutral Sentiment: Analyst sentiment remains broadly favorable. Corcept has a “Moderate Buy” consensus rating and an average price target of $138.17, with several firms maintaining or raising bullish targets. However, the stock trades at a very high earnings multiple, increasing its sensitivity to disappointments.
• Negative Sentiment: Insiders reported additional selling. Director James Wilson sold 10,000 shares for approximately $1.11 million, reducing his position by 0.93%. Joseph Lyon also sold 10,000 shares, cutting his holdings by 63.76%. Wilson still owns more than 1.06 million shares, which may temper—but does not eliminate—the negative signal from insider sales. Corcept Therapeutics insider selling report

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.